Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: A southwest oncology group study

Steven M. Grunberg, John Crowley, Robert Livingston, Indrani Gill, Stephen K. Williamson, Timothy O'Rourke, Thomas Braun, M. Ernest Marshall, James K. Weick, Stanley P. Balcerzak, Roy L. Martino

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Purpose: We designed an all-oral regimen of etoposide and cyclophosphamide for use in advanced non-small-cell lung cancer. Patients and Methods: Eligible patients were chemotherapy-naive and had histologically confirmed assessable or measurable stage IV non-small-cell lung cancer. Patients received etoposide 50 mg/m2/d orally days 1 through 14 and cyclophosphamide 50 mg/m2/d orally days 1 through 14 every 28 days. Doses on later cycles were adjusted for myelosuppression. Results: Sixty-six patients (64 eligible patients) received 192 cycles of oral extended etoposide/cyclophosphamide therapy (median, two cycles; range, zero to 15). Therapy was well tolerated with the mean dose per cycle being 104% of the originally scheduled dose. Two patients (3%) achieved a complete response and six (9%) achieved a partial response. Leukopenia, anemia, nausea/vomiting, and alopecia were the most common toxicities. Median survival was 6 months, and the 1-year survival rate was 25.6%, comparable to more intensive treatments. Conclusion: Oral extended etoposide/cyclophosphamide is a well-tolerated alternative for the treatment of stage IV non-small-cell lung cancer and can be used as a basis for the design of further outpatient regimens.

Original languageEnglish (US)
Pages (from-to)1598-1601
Number of pages4
JournalJournal of Clinical Oncology
Volume11
Issue number8
DOIs
StatePublished - Jan 1 1993

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: A southwest oncology group study'. Together they form a unique fingerprint.

  • Cite this

    Grunberg, S. M., Crowley, J., Livingston, R., Gill, I., Williamson, S. K., O'Rourke, T., Braun, T., Marshall, M. E., Weick, J. K., Balcerzak, S. P., & Martino, R. L. (1993). Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: A southwest oncology group study. Journal of Clinical Oncology, 11(8), 1598-1601. https://doi.org/10.1200/JCO.1993.11.8.1598